{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.3","value":"319"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"853"}],"units":"Participants"}],"title":"Post-dose: Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"85.2","value":"153"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"854"}],"units":"Participants"}],"title":"Pre-dose: Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.0","value":"220"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"833"}],"units":"Participants"}],"title":"Pre-dose: Cycle 3 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"120.4","value":"221"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"819"}],"units":"Participants"}],"title":"Pre-dose: Cycle 4 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"146.9","value":"239"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"727"}],"units":"Participants"}],"title":"Pre-dose: Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"92.2","value":"250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"650"}],"units":"Participants"}],"title":"Pre-dose: Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"118.7","value":"258"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"556"}],"units":"Participants"}],"title":"Pre-dose: Cycle 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.5","value":"355"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"title":"Pre-dose: Cycle 16 Day 2"}],"denoms":[{"counts":[{"groupId":"OG000","value":"952"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered atezolizumab 840 mg, IV infusion, Q2W in combination with chemotherapy (paclitaxel 80 mg/m\\^2, IV infusion QW for maximum of 22 weeks followed by dose-dense doxorubicin, 60 mg/m\\^2 or dose-dense epirubicin, 90 mg/m\\^2, IV (investigator's choice) plus cyclophosphamide, 600 mg/m\\^2, IV repeated Q2W for maximum of 17 weeks supported with G-CSF or GM-CSF treatment followed by atezolizumab, 1200 mg IV infusion every Q3W as a maintenance therapy to complete 1 year of atezolizumab treatment from the first dose.","id":"OG000","title":"Atezolizumab and Chemotherapy"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK)-evaluable population included all participants who received any dose of study medication and who have at least one evaluable postbaseline PK sample. Overall number analyzed is the number of participants with data available for analyses. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","timeFrame":"Postdose Day 1 of Cycle 1; Predose Day 1 of Cycles 2, 3, and 4; Predose Cycles 6, 10, and 14; Predose Day 2 of Cycle 16; Cycles 1-5= 28-day cycles; Cycles 6-16: 21-day cycles","title":"Serum Concentration of Atezolizumab","type":"SECONDARY","unitOfMeasure":"microgram per milliliter (µg/mL)"}